Table 2 Behavioral scores before and after treatment

From: Effect of combined naltrexone and bupropion therapy on the brain’s functional connectivity

 

Baseline, mean (SE)

1 month later, mean (SE)

Group × time

Main effect of time

Main effect of group

BMI

     

NB32

32.7 (1.2)

32.5 (1.2)

F(1,34) = 0.24

F(1,34) = 2.47

F(1,34) = 0.26

PLB

32.0 (0.7)

31.9 (0.8)

p = 0.625

p = 0.125

p = 0.615

DEBQ

     

NB32

76.5 (3.8)

74.1 (3.9)

F(1,34) = 3.97

F(1,34) = 0.08

F(1,34) = 0.02

PLB

72.8 (4.8)

76.1 (4.4)

p = 0.054

p = 0.778

p = 0.889

Craving control

     

NB32

300 (27)

232 (32)

F(1,34) = 0.23

F(1,34) = 8.40

F(1,34) = 0.15

PLB

278 (25)

229 (22)

p = 0.635

p = 0.007

p = 0.702

COEQ-Q19

     

NB32

43.4 (5.9)

30.9 (5.1)

F(1,34) = 1.97

F(1,34) = 3.76

F(1,34) = 0.01

PLB

38.8 (6.3)

36.8 (5.4)

p = 0.170

p = 0.061

p = 0.939

  1. NB32 naltrexone-sustained release (SR) 32 mg and bupropion SR 360 mg treatment group, PLB placebo group, DEBQ Dutch Eating Behavior Questionnaire, COEQ-Q19 generally, how difficult has it been to control your eating?. Bold values indicates statistically significant between NB32 and PLB